{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"79.43","value":"137.86"},{"groupId":"OG001","spread":"118.33","value":"311.67"},{"groupId":"OG002","spread":"226.69","value":"681.53"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"39"}],"units":"Participants"}],"description":"PK analysis for MOR202 4, 8 and 16 mg/kg IV once weekly dose groups only, since serum concentrations of MOR202 were substantially affected by target mediated drug disposition effects for remaining dose groups","dispersionType":"Standard Deviation","groups":[{"description":"Dosing at 4 mg/kg IV once weekly (incl. one add. dose on Cycle 1 Day 4)","id":"OG000","title":"4 mg/kg QW"},{"description":"Dosing at 8 mg/kg IV once weekly (incl. one add. dose on Cycle 1 Day 4)","id":"OG001","title":"8 mg/kg QW"},{"description":"Dosing at 16 mg/kg IV once weekly (incl. one add. dose on Cycle 1 Day 4)","id":"OG002","title":"16 mg/kg QW"}],"paramType":"MEAN","populationDescription":"Pharmakokinetics was analysed on all available data on patients receiving 4mg/kg weekly, 8mg/kg weekly and 16 mg/kg weekly irrespective in which part the patients were treated.","reportingStatus":"POSTED","timeFrame":"up to 7 days after last MOR202 dose","title":"Pharmacokinetics: Cmax - Maximum Observed Serum Concentration for MOR202","type":"SECONDARY","unitOfMeasure":"µg/mL"}